The lateral flow test can be used at the point of care and provides results within 15 minutes without the need for additional equipment, the company said.
The assay can be used to determine the immune status of COVID-19 patients and individuals who have been vaccinated against the virus, the company said.
The government said that rapid, regular testing of asymptomatic patients will be expanded to cover all 317 local authorities in the country starting next week.
The firm's Diagnostics division expects to post $1.13 billion in revenues for fiscal Q1 2021, up 262 percent from $312.0 million in the year-ago period.
Biodesix, which raised about $63 million in a recent initial public offering, said it ended 2020 with roughly $62 million in cash and cash equivalents.
One of a host of new methods used for diagnosis of and screening for COVID-19, there are still hurdles to widespread adoption of breath testing for the disease.
The firm noted that interleukin-6 ─ an intercellular messenger molecule ─ is an indicator of the potential for a severe inflammatory response in patients with confirmed SARS-CoV-2 infection.
The collaboration builds on an oligonucleotide supply agreement the partners signed in 2019 for Clear Labs' nanopore sequencing-based food safety testing.
